


PHARMACEUTICAL 2022



MARIZYME INC Rank 127 of 475







PHARMACEUTICAL 2022



MARIZYME INC Rank 127 of 475

The relative strengths and weaknesses of MARIZYME INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MARIZYME INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 441% points. The greatest weakness of MARIZYME INC is the variable Other Expenses, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 295% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	4,402
Cost of Goods Sold	0
Intangible Assets	60,057
Liabilities, Current	3,134
Liabilities, Non-Current	15,175
Other Assets	1,528
Other Compr. Net Income	0
Other Expenses	7,350
Other Liabilities	0
Other Net Income	-2,177
Property and Equipment	13
Research and Development	1,682
Revenues	210
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	65,999
Liabilities	18,309
Expenses	9,032
Stockholders Equity	47,690
Net Income	-10,998
Comprehensive Net Income	-10,998
Economic Capital Ratio	19%

